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Abstract : Currently, there is a strong unmet need for a new intervention therapy 
for hepatocellular carcinoma （HCC）.  One candidate therapy uses dendritic cells 
（DCs）, which are professional antigen-presenting cells that are characterized by 
their potent ability to elicit immune responses to foreign antigens.  DCs may be 
attractive adjuvant agents for cancer therapy but the effect of DCs therapy is 
restricted because of the immunosuppressive nature of the tumor microenvironment.  
T-cell immunoglobulin and mucin protein-3 （TIM-3） is a marker of this immuno-
suppressive tumor environment.  Interaction of TIM-3 with its ligand, galectin 9, 
triggers cell death in activated T cells.  In this study, we evaluated the antitumor 
effects of DC vaccine therapy in combination with TIM-3 blockade in a murine 
HCC system.  In an animal cancer prevention model, BALB / c mice were immu-
nized with DCs with or without anti-TIM-3 antibody before challenging with HCC 
tumor cells （BNL）.  In an animal cancer therapeutic model, BALB / c mice were 
inoculated with DCs with or without anti-TIM-3 antibody 10 days after injection 
with BNL cells.  The mechanism of this combination therapy was investigated using 
immunohistologic staining of the treated tumors and ow cytometry of lymphocytes.  
DC and anti-TIM-3 antibody combination treatment prevented tumor development 
to a greater extent than DCs alone.  In the therapeutic model, the outgrowth of 
the established tumors was signicantly reduced in mice treated with the combina-
tion of DCs and anti-TIM-3 antibody.  Immunohistological analyses of the thera-
peutic model showed marked inltration of CD4＋ cells and CD8＋ T-cells in the 
established BNL tumors of mice treated with both DCs and anti-TIM-3 antibody.  
Anti-TIM-3 antibody treatment reduces lymphocyte apoptosis and enhances the 
antitumor effect of DC therapy in a murine HCC model.
Key words : dendritic cells, T-cell immunoglobulin and mucin protein-3, hepatocel-
lular carcinoma, immunotherapy
Introduction
　Approximately 500,000 new cases of hepatocellular carcinoma （HCC） are diagnosed per 
annum worldwide.  Vaccination against hepatitis B virus （HBV） and the use of direct acting 
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antiviral agents （DAAs） therapy against hepatitis C virus （HCV） is expected to reduce the 
number of HCC patients in the future.  Nevertheless, the incidence of HCC is still increasing in 
Asia and Africa because of the prevalence of these viral infections in those regions.  Progress 
in the development of treatments for HCC has resulted in an improved prognosis for HCC 
patients.  Unfortunately HCC is usually associated with cirrhosis and often recurs even after 
effective treatment of the tumors in the remaining part of the cirrhotic liver.  Thus, there is a 
strong unmet need for the development of a new and effective intervention therapy that sup-
presses HCC occurrence or recurrence and has fewer side effects.  Initial clinical trials have 
been performed using immunotherapy and these indicate that it may be applicable to the clinical 
treatment of HCC.
　Dendritic cells （DCs） are professional antigen-presenting cells （APCs） that are characterized 
by their potent ability to activate and stimulate naïve T-lymphocytes in vivo 1）.  Immature DCs 
take up and process antigens present in the lymph node or in peripheral organs.  Antigen-
loaded DCs move to draining lymph nodes where DCs present the antigens to naïve T-cells and 
enhance their proliferation and differentiation into effector T-cells 2）.  The co-localization of DCs 
and tumor cells may generate APCs capable of stimulating tumor-reactive T cells in vivo.  The 
histologic inltration of DCs into primary tumors is associated with prolonged patient survival 
and reduces the incidence of metastatic disease in patients with bladder, lung, esophageal, gastric, 
and nasopharyngeal carcinoma 3-8）.  A number of clinical studies have been performed that indi-
cate that DCs are attractive adjuvants as well as therapeutic agents for cancer therapy in murine 
models 9-12）.  However, DC therapy is not sufcient to cure HCC because patients with these 
tumors have a suppressed immune system.
　T-cell immunoglobulin and mucin protein-3 （TIM-3） is expressed on IFN-γ-secreting T helper 
1 （Th1） cells as well as on DCs, monocytes, CD8＋ T-cells and other lymphocyte subsets 13）. 
Interaction of TIM-3 with its ligand, galectin-9, triggers cell death in TIM-3＋ T-cells, which impli-
cates TIM-3 in negatively regulating the Th1 response 14）.  The blockade of TIM-3 activity results 
in an increase in IFN-γ-secreting cells in the immunosuppressive tumor microenvironment 15, 16）. 
TIM-3 is also expressed on macrophages and monocytes and has been implicated in both the 
phagocytosis of apoptotic cells and cross-presentation 17）.  Other immune checkpoint molecules 
including cytotoxic T-lymphocyte-associated protein-4 （CTLA-4） and programmed cell death 1 
（PD-1） are currently at the forefront of cancer immunotherapy.  Anti-CTLA-4 antibody has been 
approved for the treatment of advanced melanoma, and anti-PD-1 antibody has already shown 
promise in early clinical trials 18-21）.
　We have previously reported that the combination of IFN-α gene-transduced tumor-based vac-
cination therapy in combination with anti-PD-1 antibody suppresses the outgrowth of established 
tumors in a murine colorectal cancer model 22）.  Now we propose that an anti-TIM-3 antibody 
can enhance the effect of existing immunotherapy.
　In this study, the antitumor effects of combined DC vaccine therapy with TIM-3 blockade 
were evaluated in a murine HCC system as a preliminary investigation prior to clinical studies. 
We show that the outgrowth of the established tumors is signicantly suppressed when tumor-
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bearing mice are injected with DCs and anti-TIM-3 antibody.  Furthermore, we performed immu-
nohistologic staining of the tumors and ow cytometry lymphocytes to explore the mechanism of 
the antitumor effects induced by this combination therapy.
Materials and methods
Mice
　Female 6-week-old BALB / c mice were purchased from Sankyo Lab Service （Tokyo, Japan） 
for experimental use between 8 and 12 weeks of age.  The mice were maintained in an animal 
care facility at Showa University.  The ethical committee for Animal Experiments of Showa Uni-
versity approved this study （permission #2011-1111）.
Cell lines, culture medium and reagents
　The BNL murine HCC cell line is of BALB / c origin and was maintained in RPMI-1640 
medium supplemented with 10％ heat-inactivated fetal calf serum, 100 IU penicillin and 100 µg /
ml streptomycin in a humidied incubator with 5％ CO2 in air at 37℃.  All cell culture reagents 
were purchased from Life Technologies （Gaithersburg, MD, USA）.  Phenotypically mature DCs 
and irradiated 100 Gy BNL cells were co-incubated to generate immunized DCs.  Anti-TIM-3 
antibody was purchased from eBioscience （San Diego, CA, USA）.
Preparation of DCs and incubation with tumor cells
　Bone marrow cells were isolated from BALB / c mice and DCs were generated by treatment 
of these cells with 10 ng / ml murine Granulocyte Macrophage Colony-Stimulating Factor （GM-
CSF） and 10 ng / ml Interleukin-4 （IL-4） （R&D Systems, Inc., Minneapolis, MN, USA）.  DCs 
were pre-incubated with BNL cells that had been previously γ-irradiated （100 Gy） at a DC to 
tumor cell ratio of 10 : 1 23）.
Prevention model
　BALB / c mice were immunized before tumor injection with 200 µg of anti-TIM-3 antibody, or 
with 1×10 6 DCs with or without 200 µg of anti-TIM-3 antibody in the right ank on days 1, 8 
and 15.  PBS and immunized DCs were injected subcutaneously and anti-TIM-3 antibody was 
injected intraperitoneally 24）.  On day 21, the mice were challenged with 1×10 5 BNL cells into 
the contra-lateral （left） ank and they were observed for 60 days.  Each experiment involved 
ve mice per group and was performed twice.
Therapeutic models
　In order to evaluate the potential to treat established tumors, we measured the size of 
established BNL tumors of mice treated with DCs with or without anti-TIM-3 antibody.  First, 
BALB / c mice were injected subcutaneously with 1×10 5 cell BNL in left ank.  On days 7, 9 
and 11 after the BNL inoculation, the mice were injected with 200 µl of PBS or 1×10 6 DCs or 
200 µg of anti-TIM-3 antibody into contra-lateral （right） ank.  Each experiment involved ve 
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mice per group.  Tumor size was measured twice a week using vernier calipers.  Experiments for 
this model were performed twice.
Immunohistologic analysis
　BALB / c mice were injected subcutaneously in the left ank with 5×10 5 BNL cells and after 
14, 17 and 21 days, the mice were inoculated into the contra-lateral （right） ank with 200 µl of 
PBS or 1×10 6 immunized DCs with or without 200 µg of anti-TIM-3 antibody.  Tumor tissues 
were harvested seven days after the last inoculation, and immediately embedded in optimal 
cutting temperature compound and frozen.  Serial 5-mm sections were exposed to anti-CD4, 
anti-CD8a, anti-CD11c and anti-Gr-1 antibodies and anti-TIM-3 antibody （Nippon Becton Dick-
inson, Tokyo, Japan）.  Rat IgG2a （Nippon Becton Dickinson） was used as a control antibody. 
Immunostaining was completed with the PLP Solution set （Wako Pure Chemical Industries, Ltd, 
Osaka, Japan）.  Immunoreactive cells were observed using light microscopy （×400） and counted 
in 10 elds.  Each experiment involved two mice per group.
Flow cytometry of lymphocytes from immunized mice stimulated with DCs or anti-TIM-3 antibody
　Mice were injected with 5×10 5 DCs as a vaccine three times on days 1, 8 and 14, and chal-
lenged with 5×10 5 BNL cells on day 21.  Splenocytes were harvested seven days after the tumor 
inoculation and cultured in vitro.  A total of 2×10 6 splenocytes were co-cultured with 5×10 5 
DCs with or without 100 µg of anti-TIM-3 antibody.  The cultured splenocytes were re-stimulated 
with 30 IU / ml recombinant murine IL-2 （Becton Dickinson） after seven days of culture and 
then incubated for an additional seven days.  The immunogenic effects of DCs and anti-TIM-3 
antibody were analysed by ow cytometry using a FACsCalibur （Nippon Becton Dickinson）.
　CD4＋ T-cells and CD8＋ T-cells were sorted and isolated using MACs beads （Miltenyi Biotec, 
Bergisch Gladbach, Germany） with either CD4 or CD8 beads.  The isolated cells were stained 
with fluorescein isothiocyanate （FITC）-conjugated and phycoerythrin （PE）-conjugated anti-H-
2Kb, CD4, CD8, and caspase-8 monoclonal antibodies （Medical & Biological Laboratories Co, 
Ltd, Nagoya, Japan）.  7-Amino-Actinomycin D （7-AAD） （Nippon Becton Dickinson）, which is a 
uorescent dye that intercalates with cellular DNA and undergoes a spectral shift upon associa-
tion, was used to detect dead cells.
Statistical analyses
　The comparative growth of established tumors and T-cell responses were assessed using Stu-
dent’s t-tests for two samples with unequal variances.  Differences between groups were consid-
ered signicant when the P value was less than 0.05.
Results
Combined treatment with DC vaccine and anti-TIM-3 antibody prevents development of BNL 
tumors
　BALB / c mice received three inoculations of DCs with or without anti-TIM-3 antibody.  The 
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mice were then challenged with an injection of BNL tumor cells on day 21.  The duration for 
tumor establishment in BALB / c mice as a palpable tissue was measured over 60 days.
　The mouse combination treatment group had the longest duration of tumor establishment 
compared to other treatment groups （Control vs. DCs＋ anti-TIM-3 : P＝0.0014 ; anti-TIM-3 vs. 
DCs＋ anti-TIM-3 : P＝0.0046 ; DCs vs. DCs＋ anti-TIM-3 : P＝0.0305 ; Fig. 1）.  Therefore, the 
anti-TIM-3 with the DC vaccine had a preventive effect on tumor development.  Tumor chal-
lenge was rejected for more than 60 days in half of the 10 mice treated with combined DCs 
and anti-TIM-3 antibody.  A palpable tumor was observed in all of the mice tested in other 
groups.
Therapeutic inoculations with combined DCs and anti-TIM-3 antibody suppressed the growth of 
established BNL tumors in vivo
　Mice bearing established BNL tumors were treated by an injection of DCs alone, or anti-
TIM-3 antibody alone or by a combination of both.  Seven days after the mice were injected 
with BNL cells they were injected with the DCs with or without anti-TIM-3 antibody in the 
opposite ank at three day intervals.  We observed therapeutic effects by measuring the mean 
tumor area after tumor inoculation in all ve mice in each treatment group.  The mean area 
of established tumors in mice treated with both DCs and anti-TIM-3 antibody was signicantly 
decreased compared with the area of the control group or single treatment groups （DCs＋ anti-
TIM-3 antibody vs. DCs on day 30 tumor size, P＝0.0228 ; Fig. 2）.
Fig. 1.  Treatment of mice with anti-TIM3 antibody and 
a DC vaccine prevents the development of 
BNL tumors. Mice were injected three times 
with DCs with or without anti-TIM-3 antibody. 
Seven days after the last treatment, the mice 
were inoculated with BNL tumor cells, and 
observed for 60 days to determine the number 
of tumor-free mice （Control vs. DCs ＋ anti-
TIM-3 : P＝ 0.0014, anti-TIM-3 vs. DCs＋ anti-
TIM-3 : P＝ 0.0046, DCs vs. DCs＋ anti-TIM-3 : 
P＝ 0.0305）.
Fig. 2.  Treatment of mice with DC vaccine and the 
anti-TIM-3 antibody suppressed the growth of 
established BNL tumors in vivo. Mice were 
inoculated with BNL in the flank on day 0. 
Established BNL tumors were treated three 
times with DCs alone, anti-TIM-3 antibody 
alone, or the combination in the contralateral 
flank every two days starting seven days after 
BNL cells injection.
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Combined DCs and anti-TIM-3 antibody treatment induced the inltration of CD4＋ and CD8＋  
cells in established BNL tumors
　We performed immunohistochemical staining of BNL tumor tissues from treated mice to inves-
tigate the antitumor mechanisms induced by the DC and anti-TIM-3 therapy.  There was marked 
inltration of the tumors by both CD4＋ cells and CD8＋ cells in the single anti-TIM-3 antibody 
treatment group compared to the group treated with DCs alone （Fig. 3）.  In addition, there 
was no signicant change in the inltration of DC marker CD11c＋ cells and granulocyte marker 
Gr-1＋ cells in the established tumors of every group （data not shown）.
Anti-TIM-3 antibody prevents apoptosis of lymphocytes from mice injected with BNL cells
　Flow cytometry was performed to investigate the immunogenic effects of DC treatment and 
anti-TIM-3 treatment.  Mice were injected with 1×10 6 tumor antigen-loaded DCs on the days 
1, 8 and 17.  On day 25, mice were inoculated with 1×10 5 BNL cells ; they were sacriced on 
day 32 and their spleens was harvested.  After 14 days of culture, MACs beads were used to 
isolate to CD4＋ and CD8＋ T-cell populations from the splenocytes and these were analyzed by 
ow cytometry.  Caspase-8 is a cell marker that is used to quantitatively determine the percent-
Fig. 3.  CD4＋ and CD8＋ T-cells markedly infiltrated into 
the established BNL tumors of mice inoculated with 
the combination of DCs and anti-TIM-3 antibody. 
BALB / c mice were injected subcutaneously three 
times with DCs and anti-TIM-3 antibody either 
alone or in combination into the contralateral flank 
of the established BNL tumor. Tumor tissues were 
harvested 10 days after therapeutic inoculation and 
stained with anti-CD4 and anti-CD8 antibodies. 
Immunoreactive cells were observed using light 
microscopy （×400） and counted in 10 fields.
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age of apoptotic cells within a population, whereas 7-AAD is a marker of the cell death.  Viable 
cells are caspase-8＋ and 7-AAD- ; cells that are in early apoptosis are caspase-8＋ and 7-AAD- ; 
and cells that are in late apoptosis or are dead are both caspase-8＋ and 7-AAD＋.  Treatment 
with anti-TIM-3 antibody decreased the population of caspase-8＋, 7AAD＋ T-cell subsets （Fig. 4）. 
These data indicate that addition of anti-TIM-3 antibody reduces the level of apoptosis in both 
CD4＋ and CD8＋ T-cell populations.
Discussion
　DC therapy has been used previously for patients with advanced tumors such as melanoma 
and renal cancer but the outcomes have been unsatisfactory most likely as a result of the immu-
nosuppressive environment in advanced cancer patients.  We investigated TIM-3, which has been 
identied as a marker of immune suppressor of T-cells, with the aim of improving treatment in 
clinical applications.
　TIM-3 was originally identified by its selective expression on IFN-γ-secreting Th1 and Tc1 
cells.  The interaction of TIM-3 with its ligand, galectin-9, triggers cell death in TIM-3＋ T-cells 16）. 
A recent study in patients infected with HIV showed that expression of the immune regulator 
TIM-3 is induced on exhausted CD8＋ T-cells 25）.  TIM-3 can function as a negative regulator of 
T-cell responses so that blocking TIM-3 can be effective against established tumors if TIM-3＋
PD-1＋ T cells are the predominant T-cell subset among tumor inltrating lymphocytes （TILs） at 
Fig. 4.  Blockade of TIM-3 reduced the number of apoptotic lymphocytes in mice 
immunized with BNL. Splenocytes from mice immunized with irradiated 
BNL were stimulated with DCs or anti-TIM-3 antibody. After seven days 
of culture, splenocytes were isolated to CD4＋ and CD8＋ T cells and 
stained with the 7AAD and fluorescein isothiocyanate （FITC）-conjugated 
anti-caspase-8. Numbers in each histogram indicate the percentage of 
7AAD＋ / caspase-8＋ cells in the total CD4＋ or CD8＋ population.
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the commencement of treatment 26）.
　This study was a preliminary investigation of combination therapy prior to clinical studies.  The 
anti-tumor effects of DC vaccine therapy in combination with TIM-3 blockade were evaluated 
in a murine HCC system.  Firstly, we examined the preventive effect of anti-TIM3 antibody and 
DC vaccine on tumor development.  The mice received three vaccinations with DCs with or 
without anti-TIM-3 antibody prior to injection with tumor cells.  The mice in the combination 
treatment group showed the longest duration for tumor establishment compared to other treat-
ment groups.  Secondly, we examined the therapeutic effect of DCs and anti-TIM-3 antibody in 
an established tumor model.  We treated tumor-bearing mice with DCs and anti-TIM-3 antibody, 
and observed a signicant suppression of outgrowth of the established tumors in the combination 
treatment group compared to DCs single treatment group.  These results suggest that DC and 
anti-TIM-3 antibody combination treatment has an additive antitumor effect in both the preven-
tion and therapeutic models.
　Immunohistologic analyses of the established tumors in mice treated with anti-TIM-3 antibody 
showed marked inltration of both CD4＋ and CD8＋ T-cells, compared with the control group 
and the group treated with DCs alone.  These data support the results of a previous study 
that blockade of TIM-3 signaling pathways reverses T cell exhaustion and restores antitumor 
immunity 27）.  We also demonstrated that blockade of TIM-3 reduced the level of apoptosis in 
lymphocytes in vitro.  These observations suggest that the TIM-3 blockade prevented lymphocyte 
apoptosis and maintained the survival and inltration of tumor-specic T-cells in the local tumor 
environment.
　In conclusion, our ndings suggest that the combination of DC immunotherapy and TIM-3 
blockade therapy has the potential to induce potent immune responses.  Therefore, this combina-
tion therapy should be investigated further as a possible candidate for clinical trials of cancer 
vaccines.
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